# of Displayed Technologies: 2 / 2


Categories

Precision peptide therapy for cardiac ryanopathies
TS-075234 — PROBLEM Dysregulation of the cardiac ryanodine receptor (RyR2) leads to abnormal Ca2+ release, a central driver of serious cardiovascular diseases including congestive heart failure (CHF), catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular dysplasia (ARVD…
  • College: College of Medicine (COM)
  • Inventors: Singh, Harpreet
  • Licensing Officer: Willson, Christopher

Peptide-based therapeutic intervention for Cardiac Ryanopathies
TS-062097 — Novel polypeptides and polynucleotides targeting RyR2 to address dysregulated Ca2+ release.
The cardiac ryanodine receptor channel 2 (RyR2) is known as the Ca2+ release channel of the sarcoplasmic reticulum (SR), and is believed to be a good therapeutic target in a group of certain heart diseases, known as cardiac ryanopathies. A number of mutations in the RyR2 gene have been linked to a w…
  • College: College of Medicine (COM)
  • Inventors: Singh, Harpreet
  • Licensing Officer: Willson, Christopher

Loading icon